Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 15, 2023
Discovery & Translation
PRMT5 heats up at AACR23
The enzyme target represents a synthetic lethal precision medicine opportunity for 15% of all human cancers
BioCentury | Feb 10, 2023
Discovery & Translation
Targeting PIKFYVE and SYF2 for ALS; plus new protein degraders and more
BioCentury's roundup of translational news
BioCentury | Jan 11, 2023
Finance
Facing Humira cliff, AbbVie sees return to ‘strong growth’ by 2025
CEO Gonzalez predicts immunology drugs Skyrizi and Rinvoq will surpass Humira’s peak sales in 2027, says deals could augment post-2030 picture
BioCentury | Nov 15, 2022
Regulation
Nov. 14 Quick Takes: ADC Elahere approved in ovarian cancer
Plus: Lantheus, Point in deals for pair of radiopharmaceuticals and updates from MBX, Satsuma, Moderna, Guangzhou Lupeng, Brl
BioCentury | Aug 13, 2022
Finance
Aug. 12 Quick Takes: Seagen loses Daiichi Sankyo arbitration
Plus Inflation act heads to Biden’s desk, Illumina slides after cutting guidance and updates from Unity, Larimar and more
BioCentury | Apr 27, 2022
Deals
Pfizer invests $25M in Zentalis, will advise on development of WEE1 program
Pharma lends Zentalis clinical expertise on a high-priority program, to which the biotech retains full ownership
BioCentury | Apr 13, 2022
Product Development
April 12 Quick Takes: FDA lifts clinical hold on magrolimab studies
Plus: Setback for Myovant at FDA and updates from Takeda, Ocugen, Prilenia, AbbVie and more
BioCentury | Mar 12, 2022
Discovery & Translation
UK teams identify brain changes and genetic risk factors in COVID-19 patients; plus AbbVie, BAKX and more
BioCentury’s roundup of translational news
BioCentury | Feb 10, 2022
Discovery & Translation
Translational trendspotting: a Distillery dive into neurology
Highlights include a new approach to the amyloid hypothesis, white space strategies for stroke and gene therapies
BioCentury | Dec 3, 2021
Discovery & Translation
Mapping the plasma proteome to identify drug targets; plus GSK-Vir, Codiak and more
BioCentury’s roundup of translational news
Items per page:
1 - 10 of 71